Dr. Ketchum is a highly respected, board certified physiatrist at Froedtert Hospital with an academic appointment at the Medical College of Wisconsin in Milwaukee, Wisconsin.
With over a decade of specialized experience in physical medicine and rehabilitation, Dr. Ketchum has conducted research and has extensive experience in the use of botulinum toxin injections in treating various disease states including spasticity, dystonia, and stroke.
Dr. Ketchum is currently an Assistant Professor in the Medical College’s Department of Physical Medicine & Rehabilitation and is the Residency Program Director.
XEOMIN® helps get your adult patients back to being more than upper limb spasticity.
Learn more at booth #601.
XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use, is a prescription medicine that is used to treat adults with:
See full prescribing information for complete BOXED WARNING.
The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.
The most commonly observed adverse reactions at rates specified below and greater than placebo are:
Chronic Sialorrhea: (≥4% of patients) tooth extraction, dry mouth, diarrhea, and hypertension.
Upper Limb Spasticity: (≥2% of patients) seizure, nasopharyngitis, dry mouth, upper respiratory tract infection.
Cervical Dystonia: (≥5% of patients) dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
Blepharospasm: (≥10% of patients) eyelid ptosis, dry eye, visual impairment, and dry mouth.
Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.
Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.
The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established.